ClinicalTrials.gg
Status unknownNCT04872634SNK_ASTERUpdated Jul 21, 2021

A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment

A Phase 1/2 interventional study of SNK01 (Super Natural Killer Cells 01) and GC in Non-small Cell Lung Cancer, sponsored by NKMAX Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-07-21.

Sponsored by NKMAX Co., Ltd. · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of — 123 open to participants now, 264 under way, 101 of them phase 3. Carcinoma, Non-Small-Cell Lung · Korea, Republic of.

Planned enrollment
613th of 657
24 · median 200
Started
2021
with 47 others
Phase 1/2
84 of 700
25 open now
Registered
468th of 700
by date

Among the 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, this one is the 613th largest by planned enrollment of the 657 interventional ones that give a count, is one of 48 that started in 2021, is one of 84 in phase 1/2, and was the 468th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

123 of the 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 700 studies in Carcinoma, Non-Small-Cell Lung with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial is a Single-Center, Open, Phase I/IIa Clinical Trial conducted to evaluate the safety and anti-tumor activity of SNK01 and GC +/- Cetuximab administered in combination to Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior Tyrosine Kinase Inhibitor (TKI) therapy at least once.

After the start of the clinical trial, the first 3 subjects complete the enrollment in Cohort 1 in serial order and then 3 subjects are enrolled in Cohort 2 in serial order. After this, Cohorts 1, 3 and Cohorts 2, 4 are independently processed and subjects are enrolled in serial order when new cohorts start and/or replacement subjects are required. For the subjects who are additionally enrolled after the DLT evaluation and the MTD is determined in each dose cohort, no DLT evaluation is conducted.

The subjects allotted to each cohort are administered with the SNK01 manufactured from peripheral blood mononuclear cells total 8 times over a period of about 10 weeks. Combined administration of SNK01 starts from the Cycle 2 (Week 4) of Cytotoxic Chemotherapy and SNK01 is administered at an interval of 1 week starting from the day after the administration of Cytotoxic Chemotherapy and/or Cetuximab (Visit 5-1, D23).

When no disease progression is confirmed at EOT (End of Treatment), disease progression is checked until the clinical trial is over. The adverse events which have occurred during the study period are monitored until the date when the investigator judges that no monitoring is required as the symptom has disappeared or there is no further change in the symptom or the 30th day (±3 d) from the latest date of the administration among Gemcitabine, Carboplatin and Cetuximab after the EOT, whichever comes first.

For all the subjects enrolled in the present clinical trial, safety is checked in accordance with CTCAE V5.0 and effectiveness is checked in accordance with RECIST V1.1 through the vital signs, laboratory test, adverse events, etc. during the study period.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • or cytologically diagnosed with Locally advanced or Non-small Cell Lung Cancer (TNM 8th edition). However, recurrent Non-small Cell Lung Cancer is also allowed.
  • one or more gene mutations among EGFR, ALK, and ROS1
  • TKI treated for EGFR, ALK, or ROS1 gene mutation at least once or whose progressive disease is confirmed during or after completion of the treatment
  • platinum based chemotherapy (excluding Gemcitabine), other chemotherapy or immunotherapy besides TKI treatment before. (Those who have undergone chemotherapy or adjuvant chemotherapy are also allowed.)
  • remaining toxicity resulting from previous anti-cancer therapy is grade 1 or lower in accordance with V5.0. However, those who suffer from alopecia not lower than grade 2 or neuropathy of grade 2 related to previous platinum based chemotherapy are allowed to be enrolled.
  • voluntarily decided to participate in the present clinical trial and put their signature on a subject's consent form before start of the trial
  • 20 years of age or older
  • at least one lesion measurable by v1.1
  • is 3 months or longer
  • Eastern Collaborative Oncology Group () performance status is 0 or 1 when screened
  • adequate blood and terminal organ functions
  • For fertile women: Those who have agreed to maintain abstinence (refraining from sextual intercourses with men) or use a measure of which the annual failure rate is lower than 1 % during the treatment period and for minimum 6 months (180 days) after the last administration of SNK01, GC, or Cetuximab. Women who have had their first menstrual period, not yet reached a state (amenorrhea for longer than 12 months in succession without cause other than menopause) and have not undergone surgical sterilization (ovariectomy or hysterectomy) and under the age of 55 with follicle stimulating hormone (FSH) levels of less than 40 mIU/mL are considered as fertile women. However, women who have already confirmed menopause are excluded. The examples of the contraceptive measures of which the failure rate is lower than 1 % include the following: Bilateral Tubal Ligatio, male sterilization, established and appropriate use of hormonal contraception that inhibits ovulation, hormone releasing IUD (IntraUterine Device) and copper IUD. The reliability of abstinence should be evaluated based on the clinical trial period and the daily life-style preferred by the patient. Periodic abstinence (example: calendar method, ovulation, and post-ovulation body temperature measurement method) and coitus interrupts are not acceptable contraceptive measures.
  • For men: Those who have agreed to maintain abstinence (refraining from sextual intercourses with women) as defined below, use contractiptive measures, and abstain from sperm donation. Men with a fertile spouse should maintain abstinence or use of condoms and additional contraceptive measures during the treatment period and for minimum 4 months (120 days) after the last administration of SNK01, GC or Cetuximab so that the annual failure rate is lower than 1 %. Men should abstain from sperm donation during this period. The reliability of sexual abstinence should be evaluated based on the study period and the normal life-style preferred by the patient. Periodic abstinence (example: calendar method, ovulation, and post-ovulation body temperature measurement method) and coitus interrupts are not acceptable contraceptive measures.
  • adapt themselves to the Protocol according to the judgment of the investigator

Exclusion Criteria: Subjects who fulfill ANY of the following criteria will not be enrolled into the study:

  • have taken a drug for another clinical trial or participated in another clinical trial within 30 days prior to the enrollment
  • have taken Cetuximab to cure Non-Small Cell Lung Cancer
  • a systemic or partial antineoplastic therapy is scheduled during the period of the present study
  • previous treatments meet the following criteria:

    1. Those who have undergone systemic Cytotoxic Chemotherapy, administration of a biologic agent, or a surgery within 3 weeks prior to the enrollment date
    2. Those who have undergone Breast Radiotherapy of which the radiation exceeds 30 gray (Gy) for treatment of Non-small Cell Lung Cancer within 6 months prior to the enrollment date
    3. Those who have undergone Palliative Radiotherapy on the regions to which a lung cancer is metastasized (bone, brain, etc.) within 1 week before the enrollment date
    4. Those who have undergone therapy of EGFR TKIs (Gefitinib, Erlotinib, Afatinib, Osimertinib, etc.), ALK TKIs (Crizotinib, Ceretinib, Alectinib, Brigatinib, etc.) and/or ROS1 TKIs (Crizotinib, etc.) within 2 weeks of the enrollment date
  • an anamnesis of a known allergic reaction or a serious allergic reaction to Gemcitabine, Carboplatin, or another platinum containing compound, Cetuximab or a monoclonal antibody
  • uncured or active Central Nervous System (CNS) metastasis confirmed by screening and previous CT or MRI evaluation. However, the patients who have cured or symptomless are allowed to be enrolled if they meet all the following criteria:

    1. if a lesion exists on the region other than the area of CNS metastasis that can be evaluated or measured by RECIST V1.1;
    2. if it is radiologically confirmed before the enrollment that the lesion is stabilized after the area of CNS metastasis has been treated;
    3. if the patients have no anamnesis of intracranial hemorrhage or myelorrhagia; and
    4. if the patients have clinically stable symptomless lesion for minimum 2 weeks after treatment of the CNS metastasis and stopping use of anticonvulsant or .
  • an active disorder within 2 years prior to the enrollment date which requires systemic treatment
  • undergone allogeneic stem cell or solid-organ transplant before
  • an interstitial lung disease or pneumonitis which requires orally or intravenously administered steroid treatment
  • have been inoculated or plan to be inoculated with live attenuated influenza vaccine within 30 days prior to the enrollment date
  • an active infection that requires systemic treatment through intravenous administration
  • positive for , , or
  • a medical history related to psychiatry or an anamnesis of drug abuse or alcoholism that will affect participation in the present clinical trial
  • an anamnesis of another malignant tumor within recent 5 years. However, patients with a non-melanoma skin carcinoma appropriately treated or with another cancer that shows no evidence of the disease after receiving potential treatment and for which no evidence of recurrence is found for 5 years from the starting point of the treatment by the doctor in charge are allowed to be enrolled.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    SNK01 (4ⅹ10^9 cells) + GC

    Administration of SNK01 4ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks

    Biological: SNK01 (Super Natural Killer Cells 01) · Drug: GC

  • Experimental
    SNK01 (4ⅹ10^9 cells) + GC + Cetuximab

    Administration of SNK01 4ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops

    Biological: SNK01 (Super Natural Killer Cells 01) · Drug: GC · Biological: Cetuximab

  • Experimental
    SNK01 (6ⅹ10^9 cells) + GC

    Administration of SNK01 6ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks

    Biological: SNK01 (Super Natural Killer Cells 01) · Drug: GC

  • Experimental
    SNK01 (6ⅹ10^9 cells) + GC + Cetuximab

    Administration of SNK01 6ⅹ10\^9 cells/dose 8 times at an interval of 1 week + Administration of Cytotoxic Chemotherapy (GC) up to 4 cycles at an interval of 3 weeks + Weekly administration of Cetuximab until the disease progresses or unacceptable toxicity develops

    Biological: SNK01 (Super Natural Killer Cells 01) · Drug: GC · Biological: Cetuximab

Interventions

  • Investigational Product : SNK01 (Super Natural Killer Cells 01) Principal Component : Autologous Natural Killer Cell To induce anti-tumor immunity in Locally advanced or Metastatic Non-small Cell Lung Cancer Patients who have failed prior TKI therapy for EGFR, ALK, or ROS1 Gene Mutation and to strengthen the Antibody-Dependent Cellular Cytotoxicity (ADCC) of Cetuximab, 4x10\^9 or 6x10\^9 cells are infused through the veins of the subjects within 45 minutes (±15 minutes) per 100 mL total 8 times at intervals of one week.

  • DrugGC

    Gemcitabine; 1000mg/m2, Day 1, Day 8, 4-cycle administration, Mixed with normal saline 50ml and administered into a vein for 30 min. Carboplatin; AUC 5, Day 1, 4-cycle administration, Mixed with 5% Dextrose 200ml and administered into a vein for 1 hour.

    Also known as: Cytotoxic Chemotherapy

  • BiologicalCetuximab

    First administration: 400mg/m2 Subsequent administration: 250mg/m2 (Premedication before administration\*) Weekly Administration continues until the disease progresses or unacceptable toxicity develops. 400mg/m2: Administered into a vein for 120 minutes 250mg/m2: Administered into a vein for 60 minutes

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose of the dose of SNK01 + GC + (or Cetuximab)

    Dose-Limiting Toxicity assessment

    Time frame: 28 days

  2. Adverse event

    Adverse event (AE)

    Time frame: Up to 12 months

Secondary outcomes

  1. Progression-free survival

    Progression-Free Survival (PFS)

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  2. Disease Control Rate

    Disease Control Rate (DCR)

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  3. objective response rate

    objective response rate (ORR)

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  4. Time to progression

    Time to progression (TTP)

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  5. Duration of response

    Duration of response (DoR)

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  6. QoL

    EoRTC QLQ-C30

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

  7. QoL

    EORTC QLQ-LC13

    Time frame: every 12 weeks, up to the time of death or tumor progression, maximum 24 months

07

Study locations

1 of 1 sites recruiting
  • Asan Medical Center
    Seoul, Songpa-gu 05505, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for May 2023, 22 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 22 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
May 4, 2021
StartActual
Jul 8, 2021
Primary completionEst.
May 26, 2023
CompletionEst.
May 26, 2023
Last update
Jul 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04872634
Lead sponsor
NKMAX Co., Ltd.
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Jul 8, 2021
Primary completion
May 26, 2023 (estimated)
Completion
May 26, 2023 (estimated)
Last update
Jul 21, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Troculeucel

Start the discussion